ARWR Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; Novartis Pharma AG; Madrigal Pharmaceuticals, Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.…
Industry Peers
BiotechnologyKey Statistics
About Arrowhead Pharmaceuticals (NASDAQ: ARWR)
›
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,062 employees.
The shares were at 43.94 USD on 20 November 2026, up 10.2% over 52 weeks. Its 52-week range is 37.06 USD to 95.49 USD: the price is 54.0% below the high and 18.6% above the low.
Its market capitalisation is 6.17B USD.
Arrowhead Pharmaceuticals reports an operating margin of -156.9% and revenue down 85.3% year over year.
Its debt exceeds its cash by 218.59M USD, a debt-to-equity ratio of 19.88. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 105.86 USD is 140.9% above the current price. The next earnings report is expected on 24 November 2026.